Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
ConditionProstate Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexMale
Age18+
SponsorCanadian Cancer Trials Group
About this trial
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation therapy given with a brachytherapy boost (which involves radiation sources inserted directly into the prostate)?
Eligibility criteria
Qualifiers
Histologically confirmed adenocarcinoma of the prostate diagnosed within the last 9 months
2 or 3 Intermediate Risk Factors (IRFs): cT2b-cT2c, Gleason 7 (grade group 2 or 3), and/or PSA 10-20 ng/ml;
Gleason 4+3 (grade group 3)
> 50% biopsy cores positive
Disqualifiers
Prior pelvic radiotherapy
Contraindication to radical prostate radiotherapy (e.g. connective tissue disease or inflammatory bowel disease)
Anticoagulation medication (if unsafe to discontinue for gold seed insertion or brachytherapy implant) and/or prior or current bleeding diathesis
Prior steam vaporization (Rezum), transurethral resection of the prostate (TURP), prostatectomy (simple or radical), or any ablative therapy to the prostate (cryotherapy, HIFU, TULSA, focal laser ablation, photodynamic therapy)
Trial design
Treatments tested in this trial
- Radiation
- Radiation SBRT only
- ADT
Treatment groups
710 Participants
are divided into 2 treatment groupsSponsors and collaborators
Canadian Cancer Trials Group
Lead sponsor
NRG Oncology
Collaborator
Source ClinicalTrials.gov